Ultragenyx Pharmaceutical (RARE) Preferred Stock Liabilities (2013)

Ultragenyx Pharmaceutical (RARE) reported Preferred Stock Liabilities of $51.0 million for Q4 2013.

Ultragenyx Pharmaceutical (RARE) Preferred Stock Liabilities (2013) Analysis & Trends

Ultragenyx Pharmaceutical (RARE) has 1 years of Preferred Stock Liabilities data on file, last reported at $51.0 million in Q4 2013.

Preferred Stock Liabilities for Q4 2013 came in at $51.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2013 was $51.0 million (changed N/A YoY), and the FY2013 annual result was $51.0 million, up 36.16% from the prior year.
Preferred Stock Liabilities steadied at $51.0 million in Q4 2013 per RARE's latest filing.
Over five years, Preferred Stock Liabilities peaked at $51.0 million in Q4 2013 and troughed at $51.0 million in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Ultragenyx Pharmaceutical	2.77 Bn	2.36 Bn	106.00 Mn	-

Download Data

Date	Value
Dec 31, 2013	51.00 Mn